Intrinsic value of Steris - STE

Previous Close

$117.01

  Intrinsic Value

$34.92

stock screener

  Rating & Target

str. sell

-70%

Previous close

$117.01

 
Intrinsic value

$34.92

 
Up/down potential

-70%

 
Rating

str. sell

We calculate the intrinsic value of STE stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 9.9

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  5.10
  5.09
  5.08
  5.07
  5.07
  5.06
  5.05
  5.05
  5.04
  5.04
  5.03
  5.03
  5.03
  5.03
  5.02
  5.02
  5.02
  5.02
  5.02
  5.01
  5.01
  5.01
  5.01
  5.01
  5.01
  5.01
  5.01
  5.01
  5.01
  5.00
Revenue, $m
  2,754
  2,894
  3,041
  3,195
  3,357
  3,527
  3,705
  3,892
  4,088
  4,294
  4,510
  4,737
  4,976
  5,226
  5,488
  5,764
  6,053
  6,357
  6,675
  7,010
  7,361
  7,730
  8,118
  8,524
  8,951
  9,399
  9,870
  10,364
  10,883
  11,427
Variable operating expenses, $m
  2,498
  2,609
  2,725
  2,848
  2,976
  3,111
  3,252
  3,400
  3,555
  3,719
  3,574
  3,754
  3,942
  4,141
  4,349
  4,567
  4,796
  5,037
  5,289
  5,554
  5,833
  6,125
  6,432
  6,754
  7,092
  7,448
  7,820
  8,212
  8,623
  9,054
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  2,498
  2,609
  2,725
  2,848
  2,976
  3,111
  3,252
  3,400
  3,555
  3,719
  3,574
  3,754
  3,942
  4,141
  4,349
  4,567
  4,796
  5,037
  5,289
  5,554
  5,833
  6,125
  6,432
  6,754
  7,092
  7,448
  7,820
  8,212
  8,623
  9,054
Operating income, $m
  256
  285
  315
  347
  381
  416
  453
  492
  533
  576
  937
  984
  1,033
  1,085
  1,140
  1,197
  1,257
  1,320
  1,386
  1,456
  1,529
  1,605
  1,686
  1,770
  1,859
  1,952
  2,049
  2,152
  2,260
  2,373
EBITDA, $m
  688
  723
  759
  798
  838
  881
  925
  972
  1,021
  1,072
  1,126
  1,183
  1,243
  1,305
  1,370
  1,439
  1,512
  1,587
  1,667
  1,751
  1,838
  1,930
  2,027
  2,129
  2,235
  2,347
  2,465
  2,588
  2,718
  2,854
Interest expense (income), $m
  43
  71
  77
  82
  88
  95
  101
  108
  116
  123
  132
  140
  149
  158
  168
  178
  189
  201
  212
  225
  238
  252
  266
  281
  297
  314
  332
  350
  369
  390
  411
Earnings before tax, $m
  185
  208
  233
  259
  286
  315
  345
  376
  409
  444
  797
  835
  875
  917
  961
  1,008
  1,056
  1,107
  1,161
  1,218
  1,277
  1,339
  1,404
  1,473
  1,545
  1,620
  1,699
  1,783
  1,870
  1,962
Tax expense, $m
  50
  56
  63
  70
  77
  85
  93
  102
  111
  120
  215
  225
  236
  248
  260
  272
  285
  299
  314
  329
  345
  361
  379
  398
  417
  437
  459
  481
  505
  530
Net income, $m
  135
  152
  170
  189
  209
  230
  252
  275
  299
  324
  581
  609
  639
  669
  702
  736
  771
  808
  848
  889
  932
  977
  1,025
  1,075
  1,127
  1,183
  1,240
  1,301
  1,365
  1,432

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  5,464
  5,742
  6,033
  6,339
  6,661
  6,998
  7,351
  7,722
  8,112
  8,520
  8,949
  9,400
  9,872
  10,368
  10,889
  11,436
  12,010
  12,612
  13,245
  13,909
  14,606
  15,338
  16,106
  16,913
  17,760
  18,649
  19,583
  20,563
  21,592
  22,673
Adjusted assets (=assets-cash), $m
  5,464
  5,742
  6,033
  6,339
  6,661
  6,998
  7,351
  7,722
  8,112
  8,520
  8,949
  9,400
  9,872
  10,368
  10,889
  11,436
  12,010
  12,612
  13,245
  13,909
  14,606
  15,338
  16,106
  16,913
  17,760
  18,649
  19,583
  20,563
  21,592
  22,673
Revenue / Adjusted assets
  0.504
  0.504
  0.504
  0.504
  0.504
  0.504
  0.504
  0.504
  0.504
  0.504
  0.504
  0.504
  0.504
  0.504
  0.504
  0.504
  0.504
  0.504
  0.504
  0.504
  0.504
  0.504
  0.504
  0.504
  0.504
  0.504
  0.504
  0.504
  0.504
  0.504
Average production assets, $m
  2,619
  2,752
  2,892
  3,039
  3,192
  3,354
  3,523
  3,701
  3,888
  4,084
  4,289
  4,505
  4,732
  4,970
  5,219
  5,481
  5,756
  6,045
  6,348
  6,667
  7,001
  7,351
  7,720
  8,106
  8,512
  8,939
  9,386
  9,856
  10,349
  10,867
Working capital, $m
  410
  431
  453
  476
  500
  525
  552
  580
  609
  640
  672
  706
  741
  779
  818
  859
  902
  947
  995
  1,044
  1,097
  1,152
  1,210
  1,270
  1,334
  1,400
  1,471
  1,544
  1,621
  1,703
Total debt, $m
  1,420
  1,526
  1,638
  1,756
  1,879
  2,009
  2,144
  2,287
  2,436
  2,593
  2,758
  2,931
  3,113
  3,303
  3,503
  3,713
  3,933
  4,165
  4,408
  4,663
  4,930
  5,211
  5,506
  5,816
  6,141
  6,483
  6,841
  7,218
  7,613
  8,028
Total liabilities, $m
  2,098
  2,205
  2,317
  2,434
  2,558
  2,687
  2,823
  2,965
  3,115
  3,272
  3,437
  3,609
  3,791
  3,981
  4,181
  4,391
  4,612
  4,843
  5,086
  5,341
  5,609
  5,890
  6,185
  6,495
  6,820
  7,161
  7,520
  7,896
  8,291
  8,706
Total equity, $m
  3,366
  3,537
  3,717
  3,905
  4,103
  4,310
  4,528
  4,757
  4,997
  5,249
  5,513
  5,790
  6,081
  6,387
  6,708
  7,044
  7,398
  7,769
  8,159
  8,568
  8,997
  9,448
  9,921
  10,418
  10,940
  11,488
  12,063
  12,667
  13,301
  13,967
Total liabilities and equity, $m
  5,464
  5,742
  6,034
  6,339
  6,661
  6,997
  7,351
  7,722
  8,112
  8,521
  8,950
  9,399
  9,872
  10,368
  10,889
  11,435
  12,010
  12,612
  13,245
  13,909
  14,606
  15,338
  16,106
  16,913
  17,760
  18,649
  19,583
  20,563
  21,592
  22,673
Debt-to-equity ratio
  0.420
  0.430
  0.440
  0.450
  0.460
  0.470
  0.470
  0.480
  0.490
  0.490
  0.500
  0.510
  0.510
  0.520
  0.520
  0.530
  0.530
  0.540
  0.540
  0.540
  0.550
  0.550
  0.560
  0.560
  0.560
  0.560
  0.570
  0.570
  0.570
  0.570
Adjusted equity ratio
  0.616
  0.616
  0.616
  0.616
  0.616
  0.616
  0.616
  0.616
  0.616
  0.616
  0.616
  0.616
  0.616
  0.616
  0.616
  0.616
  0.616
  0.616
  0.616
  0.616
  0.616
  0.616
  0.616
  0.616
  0.616
  0.616
  0.616
  0.616
  0.616
  0.616

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  135
  152
  170
  189
  209
  230
  252
  275
  299
  324
  581
  609
  639
  669
  702
  736
  771
  808
  848
  889
  932
  977
  1,025
  1,075
  1,127
  1,183
  1,240
  1,301
  1,365
  1,432
Depreciation, amort., depletion, $m
  432
  438
  444
  451
  457
  464
  472
  480
  488
  497
  190
  199
  209
  220
  231
  243
  255
  267
  281
  295
  310
  325
  342
  359
  377
  396
  415
  436
  458
  481
Funds from operations, $m
  567
  590
  614
  639
  666
  694
  724
  755
  787
  821
  771
  809
  848
  889
  933
  978
  1,026
  1,076
  1,129
  1,184
  1,242
  1,303
  1,367
  1,434
  1,504
  1,578
  1,656
  1,737
  1,823
  1,913
Change in working capital, $m
  20
  21
  22
  23
  24
  25
  27
  28
  29
  31
  32
  34
  35
  37
  39
  41
  43
  45
  47
  50
  52
  55
  58
  61
  64
  67
  70
  74
  77
  81
Cash from operations, $m
  547
  569
  592
  617
  642
  669
  697
  727
  758
  790
  739
  775
  813
  852
  893
  937
  983
  1,031
  1,081
  1,134
  1,189
  1,248
  1,309
  1,373
  1,441
  1,511
  1,586
  1,664
  1,746
  1,832
Maintenance CAPEX, $m
  -110
  -116
  -122
  -128
  -134
  -141
  -148
  -156
  -164
  -172
  -181
  -190
  -199
  -209
  -220
  -231
  -243
  -255
  -267
  -281
  -295
  -310
  -325
  -342
  -359
  -377
  -396
  -415
  -436
  -458
New CAPEX, $m
  -126
  -133
  -140
  -147
  -154
  -162
  -169
  -178
  -187
  -196
  -206
  -216
  -227
  -238
  -250
  -262
  -275
  -289
  -303
  -318
  -334
  -351
  -368
  -387
  -406
  -426
  -448
  -470
  -493
  -518
Cash from investing activities, $m
  -236
  -249
  -262
  -275
  -288
  -303
  -317
  -334
  -351
  -368
  -387
  -406
  -426
  -447
  -470
  -493
  -518
  -544
  -570
  -599
  -629
  -661
  -693
  -729
  -765
  -803
  -844
  -885
  -929
  -976
Free cash flow, $m
  310
  320
  331
  342
  354
  366
  379
  393
  407
  422
  353
  369
  387
  405
  424
  444
  465
  487
  510
  535
  560
  587
  615
  645
  676
  708
  743
  779
  816
  856
Issuance/(repayment) of debt, $m
  104
  107
  112
  118
  123
  129
  136
  142
  150
  157
  165
  173
  181
  191
  200
  210
  220
  231
  243
  255
  268
  281
  295
  310
  325
  341
  359
  376
  395
  415
Issuance/(repurchase) of shares, $m
  25
  19
  10
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  129
  126
  122
  118
  123
  129
  136
  142
  150
  157
  165
  173
  181
  191
  200
  210
  220
  231
  243
  255
  268
  281
  295
  310
  325
  341
  359
  376
  395
  415
Total cash flow (excl. dividends), $m
  439
  446
  452
  459
  477
  496
  515
  535
  557
  579
  517
  542
  568
  595
  624
  654
  685
  719
  753
  790
  828
  868
  910
  955
  1,001
  1,050
  1,101
  1,155
  1,211
  1,271
Retained Cash Flow (-), $m
  -160
  -171
  -180
  -189
  -198
  -208
  -218
  -229
  -240
  -252
  -264
  -277
  -291
  -306
  -321
  -337
  -354
  -371
  -390
  -409
  -429
  -451
  -473
  -497
  -522
  -548
  -575
  -604
  -634
  -666
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  279
  275
  273
  271
  279
  288
  297
  307
  317
  327
  253
  265
  277
  290
  303
  317
  332
  347
  364
  381
  399
  417
  437
  458
  479
  502
  526
  551
  577
  605
Discount rate, %
  4.80
  5.04
  5.29
  5.56
  5.83
  6.13
  6.43
  6.75
  7.09
  7.45
  7.82
  8.21
  8.62
  9.05
  9.50
  9.98
  10.48
  11.00
  11.55
  12.13
  12.74
  13.37
  14.04
  14.74
  15.48
  16.25
  17.07
  17.92
  18.82
  19.76
PV of cash for distribution, $m
  266
  249
  233
  218
  210
  202
  192
  182
  171
  160
  111
  103
  95
  86
  78
  69
  61
  53
  46
  39
  32
  26
  21
  17
  13
  10
  7
  5
  4
  3
Current shareholders' claim on cash, %
  99.7
  99.6
  99.5
  99.5
  99.5
  99.5
  99.5
  99.5
  99.5
  99.5
  99.5
  99.5
  99.5
  99.5
  99.5
  99.5
  99.5
  99.5
  99.5
  99.5
  99.5
  99.5
  99.5
  99.5
  99.5
  99.5
  99.5
  99.5
  99.5
  99.5

STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others. Its Corporate and other segment includes the Defense and Industrial business unit.

FINANCIAL RATIOS  of  Steris (STE)

Valuation Ratios
P/E Ratio 90.4
Price to Sales 3.8
Price to Book 3.6
Price to Tangible Book
Price to Cash Flow 23.4
Price to Free Cash Flow 39.6
Growth Rates
Sales Growth Rate 16.7%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 37.3%
Cap. Spend. - 3 Yr. Gr. Rate 15%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 52.8%
Total Debt to Equity 52.8%
Interest Coverage 5
Management Effectiveness
Return On Assets 2.6%
Ret/ On Assets - 3 Yr. Avg. 4.6%
Return On Total Capital 2.5%
Ret/ On T. Cap. - 3 Yr. Avg. 4.8%
Return On Equity 3.8%
Return On Equity - 3 Yr. Avg. 7.3%
Asset Turnover 0.5
Profitability Ratios
Gross Margin 39.3%
Gross Margin - 3 Yr. Avg. 40.4%
EBITDA Margin 15.9%
EBITDA Margin - 3 Yr. Avg. 16.3%
Operating Margin 8.7%
Oper. Margin - 3 Yr. Avg. 10.2%
Pre-Tax Margin 7.1%
Pre-Tax Margin - 3 Yr. Avg. 8.7%
Net Profit Margin 4.2%
Net Profit Margin - 3 Yr. Avg. 5.5%
Effective Tax Rate 40%
Eff/ Tax Rate - 3 Yr. Avg. 36.8%
Payout Ratio 84.5%

STE stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the STE stock intrinsic value calculation we used $2619.996 million for the last fiscal year's total revenue generated by Steris. The default revenue input number comes from 0001 income statement of Steris. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our STE stock valuation model: a) initial revenue growth rate of 5.1% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.8%, whose default value for STE is calculated based on our internal credit rating of Steris, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Steris.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of STE stock the variable cost ratio is equal to 91.3%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for STE stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Steris.

Corporate tax rate of 27% is the nominal tax rate for Steris. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the STE stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for STE are equal to 95.1%.

Life of production assets of 22.6 years is the average useful life of capital assets used in Steris operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for STE is equal to 14.9%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $3205.96 million for Steris - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 84.552 million for Steris is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Steris at the current share price and the inputted number of shares is $9.9 billion.

RELATED COMPANIES Price Int.Val. Rating
HRC Hill-Rom Holdi 96.54 61.32  sell
MMM 3M 199.81 232.48  hold
SYK Stryker 172.61 100.38  sell
JNJ Johnson&Johnso 147.10 176.79  buy
CNMD CONMED 67.61 45.97  sell
OMI Owens&Minor 6.87 114.18  str.buy

COMPANY NEWS

▶ Is Steris Plc (STE) A Good Stock To Buy?   [Dec-15-18 01:27AM  Insider Monkey]
▶ STERIS Announces Targeted Restructuring Plan   [Dec-04-18 04:31PM  GlobeNewswire]
▶ Is STERIS plcs (NYSE:STE) ROE Of 10% Impressive?   [Nov-09-18 11:43AM  Simply Wall St.]
▶ Steris: Fiscal 2Q Earnings Snapshot   [09:03AM  Associated Press]
▶ Steris: Fiscal 1Q Earnings Snapshot   [08:45AM  Associated Press]
▶ STERIS plc to Host Earnings Call   [08:00AM  ACCESSWIRE]
▶ Steris: Fiscal 4Q Earnings Snapshot   [May-09-18 06:35AM  Associated Press]
▶ Varex Imaging Names Rosebrough To Board Of Directors   [Apr-23-18 08:30AM  PR Newswire]
▶ CME, Estee Lauder, Roku & avoid this tech name   [Feb-20-18 02:42PM  CNBC Videos]
▶ STERIS plc to Host Earnings Call   [Feb-07-18 07:50AM  ACCESSWIRE]
▶ Steris beats 3Q profit forecasts   [06:29AM  Associated Press]
▶ Stocks Generating Improved Relative Strength: Steris   [Jan-16-18 03:00AM  Investor's Business Daily]
▶ Is It Too Late To Buy Steris Plc (NYSE:STE)?   [Jan-03-18 04:48PM  Simply Wall St.]
▶ STERIS Plc Value Analysis (NYSE:STE) : November 6, 2017   [Nov-06-17 01:19PM  Capital Cube]
▶ STERIS plc to Host Earnings Call   [Nov-01-17 08:00AM  ACCESSWIRE]
▶ Steris misses 2Q profit forecasts   [06:11AM  Associated Press]
▶ Should You Buy STERIS (STE) Ahead of Earnings?   [Oct-30-17 08:56AM  Zacks]
▶ ETFs with exposure to STERIS Plc : October 16, 2017   [Oct-16-17 09:59AM  Capital Cube]
▶ 5 MedTech Momentum Picks Investors Will Love   [Oct-13-17 09:27AM  Zacks]
▶ 5 MedTech Stocks for Stellar Returns in Q3   [Oct-10-17 04:59PM  Zacks]
▶ ETFs with exposure to STERIS Plc : October 3, 2017   [Oct-03-17 11:37AM  Capital Cube]
▶ When Should You Sell Steris Plc (STE)?   [Sep-29-17 03:02PM  Simply Wall St.]
▶ How Much Higher Can Medtech Climb As Investors Flee Pharma?   [Sep-14-17 05:36PM  Investor's Business Daily]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.